Screens 100+ cancer-associated genes in a single comprehensive test
Uses Whole Exome Sequencing (WES) — far more thorough than basic BRCA-only tests
Processed in NABL and CAP-accredited genomics labs for clinical-grade accuracy
Includes FREE pre and post-report consultation with a certified Genetic Counselor
Covers breast, ovarian, colorectal, prostate, pancreatic, gastric, and other hereditary cancers
Variants classified per ACMG guidelines — trusted by physicians and geneticists
At-home saliva or blood draw — no clinic visit required
Detailed clinical data and raw data access available for healthcare professionals
Hereditary Breast & Ovarian Cancer Panel (BRCA1, BRCA2, PALB2, CHEK2, ATM)
Lynch Syndrome Panel (MLH1, MSH2, MSH3, MSH6, PMS2)
Colorectal Cancer Panel (APC, MUTYH, SMAD4, BMPR1A)
Li-Fraumeni Syndrome (TP53)
Cowden Syndrome (PTEN)
Hereditary Diffuse Gastric Cancer (CDH1)
Peutz-Jeghers Syndrome (STK11)
Pancreatic Cancer Risk Genes
Prostate Cancer Risk Genes
100+ genes total across hereditary cancer syndromes
Whole Exome Sequencing (WES) using Next-Generation Sequencing (NGS) to analyze the protein-coding regions of 100+ cancer-associated genes. Variants are classified according to ACMG/AMP guidelines (Pathogenic, Likely Pathogenic, Variant of Uncertain Significance, Likely Benign, Benign). Processed in NABL and CAP-accredited genomics laboratories. Report reviewed by certified genetic counselors.